FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc.
18/06/2026 18:01
FTC requiring Aurobindo Pharma to divest from four drug products to complete acquistion of Lannett Company Inc. June 18 (Reuters) - The U.S. Federal Trade Commission is requiring Aurobindo Pharma Limited ARBN.NS to divest four different generic drug products to complete its $250 million acquisition of Lannett Company Inc., the agency said on Thursday in a statement.
(Reporting by Ryan Patrick Jones, Writing by Christian Martinez; Editing by Doina Chiacu)
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11